[Allogeneic haematopoietic cell transplantation for indolent lymphomas: Guidelines from the Francophone Society Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

{"article_title":"[Allogeneic haematopoietic cell transplantation for indolent lymphomas: Guidelines from the Francophone Society Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].","author":"Gauthier J, Chantepie S, Bouabdallah K, Jost E, Nguyen S, Gac AC, Damaj G, Dul\u00e9ry R, Michallet M, Delage J, Lewalle P, Morschhauser F, Salles G, Yakoub-Agha I, Cornillon J","journal_title":"Bulletin du cancer","issn":"1769-6917","isbn":"","publication_date":"2017-12-01","volume":"104","issue":"12S","first_page":"S121","page_count":"","accession_number":"29173973","doi":"10.1016\/j.bulcan.2017.05.010","publisher":"Elsevier","doctype":"Consensus Development Conference","subjects":"Hematopoietic Stem Cell Transplantation standards; Leukemia, Lymphocytic, Chronic, B-Cell therapy; Lymphoma, Follicular therapy; Lymphoma, Mantle-Cell therapy; Waldenstrom Macroglobulinemia therapy; Algorithms; Allografts; Decision Making; France; Humans; Recurrence; Societies, Medical","interest_area":["Oncology"],"abstract":"Despite great improvements in the outcome of patients with lymphoma, some may still relapse or present with primary refractory disease. In these situations, allogeneic hematopoietic cell transplantation is a potentially curative option, this is true particularly the case of relapse after autologous stem cell transplantation. Recently, novel agents such as anti-PD1 and BTK inhibitors have started to challenge the use of allogeneic hematopoietic cell transplantation for relapsed or refractory lymphoma. During the 2016 annual workshop of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC), we performed a comprehensive review of the literature published in the last 10 years and established guidelines to clarify the indications and transplant modalities in this setting. This paper specifically reports on our conclusions regarding indolent lymphomas, mainly follicular lymphoma and chronic lymphocytic leukemia. Copyright \u00a9 2017 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=29173973","isPdfLink":false,"isSAML":false,"an":"29173973","number_other":"","type_pub":"","issn_electronic":"1769-6917","languages":"French","language":"fre","date_entry":"Date Created: 20171128 Date Completed: 20171228 Latest Revision: 20171228","date_update":"20240104","titleSource":"Bulletin du cancer [Bull Cancer] 2017 Dec; Vol. 104 (12S), pp. S121-S130. Date of Electronic Publication: 2017 Nov 22.","date_pub_cy":"","type_document":"","contract_publisher":"","authored_on":"2017-12-01","description":"Despite great improvements in the outcome of patients with lymphoma, some may still relapse or present with primary refractory disease. In these situations, allogeneic hematopoietic cell transplantation is a potentially curative option, this is true particularly the case of relapse after autologous stem cell transplantation. Recently, novel agents such as anti-PD1 and BTK inhibitors have started to challenge the use of allogeneic hematopoietic cell transplantation for relapsed or refractory lymphoma. During the 2016 annual workshop of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC), we performed a comprehensive review of the literature published in the last 10 years and established guidelines to clarify the indications and transplant modalities in this setting. This paper specifically reports on our conclusions regarding indolent lymphomas, mainly follicular lymphoma and chronic lymphocytic leukemia.<br \/> (Copyright © 2017 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&scope=site&db=mdl&AN=29173973&authtype=shib&custid=ns346513&group=main&profile=eds","no_of_pages":"","authored_by":"Gauthier J, Chantepie S, Bouabdallah K, Jost E, Nguyen S, Gac AC, Damaj G, Dul\u00e9ry R, Michallet M, Delage J, Lewalle P, Morschhauser F, Salles G, Yakoub-Agha I, Cornillon J"}